Alcon Inc.

Alcon Inc. is a Swiss-American pharmaceutical and medical device company that specializes in eye care products, positioning itself as a global leader in the industry. Incorporated in Fribourg, Switzerland, with its global headquarters in Geneva, Switzerland, the company also maintains a significant operational base in Fort Worth, Texas, United States. Its mission is to provide innovative products that enhance the quality of life by helping people see better.

Alcon's business is primarily divided into two segments: Surgical and Vision Care. The Surgical segment offers a comprehensive range of products including intraocular lenses (IOLs), ophthalmic surgical equipment, and consumables used in cataract, retinal, refractive, and glaucoma surgeries. The Vision Care segment provides contact lenses, such as daily disposable, reusable, and color-enhancing options, along with lens care products and various ocular health solutions for conditions like dry eye, allergies, and glaucoma.

Led by CEO David J. Endicott, Alcon operates in over 140 countries, serving a broad global patient base. The company was spun off from Novartis in April 2019, becoming an independent publicly traded entity. Recent activities include the approval of all resolutions at its 2026 Annual General Meeting on April 30, 2026, and the launch of Clareon TruPlus, an enhanced design monofocal and toric IOL, at ASCRS 2026 on April 6, 2026. Alcon reported annual net sales of $9.91 billion in 2024, with anticipated revenue between $10.2 billion and $10.4 billion for 2025, reflecting its strong market position.